665 related articles for article (PubMed ID: 24097439)
21. Six Versus 12 Months of Dual Antiplatelet Therapy After Implantation of Biodegradable Polymer Sirolimus-Eluting Stent: Randomized Substudy of the I-LOVE-IT 2 Trial.
Han Y; Xu B; Xu K; Guan C; Jing Q; Zheng Q; Li X; Zhao X; Wang H; Zhao X; Li X; Yu P; Zang H; Wang Z; Cao X; Zhang J; Pang W; Li J; Yang Y; Dangas GD
Circ Cardiovasc Interv; 2016 Feb; 9(2):e003145. PubMed ID: 26858080
[TBL] [Abstract][Full Text] [Related]
22. Reduced antiplatelet therapy after drug-eluting stenting: multicenter Janus Flex carbostent implantation with short dual antiplatelet treatment for 2 or 6 months-MATRIX study.
Cassese S; De Luca G; Villari B; Berti S; Bellone P; Alfieri A; Montinaro A; Quaranta G; Marraccini P; Piscione F;
Catheter Cardiovasc Interv; 2012 Sep; 80(3):408-16. PubMed ID: 21735531
[TBL] [Abstract][Full Text] [Related]
23. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions.
Mauri L; Kereiakes DJ; Normand SL; Wiviott SD; Cohen DJ; Holmes DR; Bangalore S; Cutlip DE; Pencina M; Massaro JM
Am Heart J; 2010 Dec; 160(6):1035-41, 1041.e1. PubMed ID: 21146655
[TBL] [Abstract][Full Text] [Related]
24. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
Berger PB; Bhatt DL; Fuster V; Steg PG; Fox KA; Shao M; Brennan DM; Hacke W; Montalescot G; Steinhubl SR; Topol EJ;
Circulation; 2010 Jun; 121(23):2575-83. PubMed ID: 20516378
[TBL] [Abstract][Full Text] [Related]
25. Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial.
Helft G; Steg PG; Le Feuvre C; Georges JL; Carrie D; Dreyfus X; Furber A; Leclercq F; Eltchaninoff H; Falquier JF; Henry P; Cattan S; Sebagh L; Michel PL; Tuambilangana A; Hammoudi N; Boccara F; Cayla G; Douard H; Diallo A; Berman E; Komajda M; Metzger JP; Vicaut E;
Eur Heart J; 2016 Jan; 37(4):365-74. PubMed ID: 26364288
[TBL] [Abstract][Full Text] [Related]
26. Rationale and design of The Intracoronary Stenting and Antithrombotic Regimen-Testing of a six-week versus a six-month clopidogrel treatment Regimen In Patients with concomitant aspirin and oraL anticoagulant therapy following drug-Eluting stenting (ISAR-TRIPLE) study.
Fiedler KA; Byrne RA; Schulz S; Sibbing D; Mehilli J; Ibrahim T; Maeng M; Laugwitz KL; Kastrati A; Sarafoff N
Am Heart J; 2014 Apr; 167(4):459-465.e1. PubMed ID: 24655693
[TBL] [Abstract][Full Text] [Related]
27. Clopidogrel Versus Aspirin as an Antiplatelet Monotherapy After 12-Month Dual-Antiplatelet Therapy in the Era of Drug-Eluting Stents.
Park TK; Song YB; Ahn J; Carriere KC; Hahn JY; Yang JH; Choi SH; Choi JH; Lee SH; Gwon HC
Circ Cardiovasc Interv; 2016 Jan; 9(1):e002816. PubMed ID: 26755571
[TBL] [Abstract][Full Text] [Related]
28. Comparison of Triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and -LONG Trials).
Lee SW; Chun KJ; Park SW; Kim HS; Kim YH; Yun SC; Kim WJ; Lee JY; Park DW; Lee CW; Hong MK; Rhee KS; Chae JK; Ko JK; Park JH; Lee JH; Choi SW; Jeong JO; Seong IW; Jon S; Cho YH; Lee NH; Kim JH; Park SJ
Am J Cardiol; 2010 Jan; 105(2):168-73. PubMed ID: 20102913
[TBL] [Abstract][Full Text] [Related]
29. Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents.
Hermiller JB; Krucoff MW; Kereiakes DJ; Windecker S; Steg PG; Yeh RW; Cohen DJ; Cutlip DE; Massaro JM; Hsieh WH; Mauri L;
JACC Cardiovasc Interv; 2016 Jan; 9(2):138-47. PubMed ID: 26793956
[TBL] [Abstract][Full Text] [Related]
30. Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy).
Stefanescu Schmidt AC; Kereiakes DJ; Cutlip DE; Yeh RW; D'Agostino RB; Massaro JM; Hsieh WH; Mauri L;
Circulation; 2017 May; 135(18):1720-1732. PubMed ID: 28228427
[TBL] [Abstract][Full Text] [Related]
31. Short-term follow-up of tirofiban as alternative therapy for urgent surgery patients with an implanted coronary drug-eluting stent after ST-elevation myocardial infarction.
Xia JG; Qu Y; Shen H; Liu XH
Coron Artery Dis; 2013 Sep; 24(6):522-6. PubMed ID: 23900046
[TBL] [Abstract][Full Text] [Related]
32. Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study.
Secemsky EA; Yeh RW; Kereiakes DJ; Cutlip DE; Steg PG; Massaro JM; Apruzzese PK; Mauri L;
JACC Cardiovasc Interv; 2017 May; 10(9):942-954. PubMed ID: 28473118
[TBL] [Abstract][Full Text] [Related]
33. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.
Valgimigli M; Campo G; Monti M; Vranckx P; Percoco G; Tumscitz C; Castriota F; Colombo F; Tebaldi M; Fucà G; Kubbajeh M; Cangiano E; Minarelli M; Scalone A; Cavazza C; Frangione A; Borghesi M; Marchesini J; Parrinello G; Ferrari R;
Circulation; 2012 Apr; 125(16):2015-26. PubMed ID: 22438530
[TBL] [Abstract][Full Text] [Related]
34. Three-month dual antiplatelet therapy after implantation of zotarolimus-eluting stents: the DATE (Duration of Dual Antiplatelet Therapy AfterImplantation of Endeavor Stent) registry.
Hahn JY; Song YB; Choi JH; Choi SH; Lee SY; Park HS; Hur SH; Lee S; Han KR; Rha SW; Cho BR; Park JS; Yoon J; Lim DS; Lee SH; Gwon HC;
Circ J; 2010 Nov; 74(11):2314-21. PubMed ID: 20938098
[TBL] [Abstract][Full Text] [Related]
35. Safety of 6-month duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndromes: Rationale and design of the Smart Angioplasty Research Team-safety of 6-month duration of Dual Antiplatelet Therapy after percutaneous coronary intervention in patients with acute coronary syndromes (SMART-DATE) prospective multicenter randomized trial.
Lee JM; Cho DK; Hahn JY; Song YB; Park TK; Oh JH; Lee JB; Doh JH; Kim SH; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC
Am Heart J; 2016 Dec; 182():1-8. PubMed ID: 27914488
[TBL] [Abstract][Full Text] [Related]
36. Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Chen KY; Rha SW; Li YJ; Poddar KL; Jin Z; Minami Y; Wang L; Kim EJ; Park CG; Seo HS; Oh DJ; Jeong MH; Ahn YK; Hong TJ; Kim YJ; Hur SH; Seong IW; Chae JK; Cho MC; Bae JH; Choi DH; Jang YS; Chae IH; Kim CJ; Yoon JH; Chung WS; Seung KB; Park SJ;
Circulation; 2009 Jun; 119(25):3207-14. PubMed ID: 19528339
[TBL] [Abstract][Full Text] [Related]
37. Study design of the influence of SErotonin inhibition on patients with RENAl impairment or diabetes undergoing drug-eluting stent implantation (SERENADE) study: A multicenter, open-label, prospective, randomized study.
Lee SA; Suh JW; Park JJ; Yoon CH; Cho YS; Youn TJ; Chae IH; Kim HS; Kim SH; Choi DJ
Contemp Clin Trials; 2015 Jul; 43():20-4. PubMed ID: 25891091
[TBL] [Abstract][Full Text] [Related]
38. Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry).
Lee SW; Park SW; Yun SC; Kim YH; Park DW; Kim WJ; Lee JY; Lee CW; Hong MK; Kim JJ; Park SJ
Am Heart J; 2010 Feb; 159(2):284-291.e1. PubMed ID: 20152228
[TBL] [Abstract][Full Text] [Related]
39. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients).
Lee SW; Park SW; Kim YH; Yun SC; Park DW; Lee CW; Hong MK; Kim HS; Ko JK; Park JH; Lee JH; Choi SW; Seong IW; Cho YH; Lee NH; Kim JH; Chun KJ; Park SJ
J Am Coll Cardiol; 2008 Mar; 51(12):1181-7. PubMed ID: 18355656
[TBL] [Abstract][Full Text] [Related]
40. Aspirin and clopidogrel with or without phenprocoumon after drug eluting coronary stent placement in patients on chronic oral anticoagulation.
Sarafoff N; Ndrepepa G; Mehilli J; Dörrler K; Schulz S; Iijima R; Byrne R; Schömig A; Kastrati A
J Intern Med; 2008 Nov; 264(5):472-80. PubMed ID: 18624903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
